Product Description
XVIR-110, also known as NM2CAB, is an aqueous nanocrystalline formulation of a novel cabotegravir prodrug, which can be administered as an intramuscular injection. Preclinical pharmacokinetic and toxicology studies conducted to date support the development of XVIR-110 as a potential once-yearly antiretroviral therapeutic for HIV treatment and prevention. (Sourced from: https://www.globenewswire.com/news-release/2021/06/08/2243462/0/en/Exavir-Therapeutics-announces-the-publication-of-preclinical-data-for-the-ultra-long-acting-integrase-inhibitor-XVIR-110-in-Nature-Communications-affirming-its-unique-pharmacokinet.html)
Mechanisms of Action: HIV Integrase Inhibitor
Novel Mechanism: No
Modality: Unknown
Route of Administration: Intramuscular
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Exavir Therapeutics
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: HIV Infections
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|